Goldman Sachs
INBX

Goldman Sachs’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Goldman Sachs’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-376,540
Closed -$13.2M – 6088
2024
Q1 		$13.2M Buy
376,540
+223,360
+146% +$8.15M ﹤0.01% 2224
2023
Q4 		$5.82M Sell
153,180
-6,289
-4% -$135K ﹤0.01% 3028
2023
Q3 		$2.93M Sell
159,469
-90,948
-36% -$1.9M ﹤0.01% 3456
2023
Q2 		$6.5M Buy
250,417
+75,236
+43% +$1.76M ﹤0.01% 2865
2023
Q1 		$3.31M Buy
175,181
+2,961
+2% +$68.9K ﹤0.01% 3437
2022
Q4 		$4.24M Buy
172,220
+16,916
+11% +$497K ﹤0.01% 3312
2022
Q3 		$2.79M Buy
155,304
+74,857
+93% +$1.35M ﹤0.01% 3671
2022
Q2 		$914K Sell
80,447
-64,032
-44% -$942K ﹤0.01% 4681
2022
Q1 		$3.22M Buy
144,479
+22,413
+18% +$572K ﹤0.01% 3786
2021
Q4 		$5.33M Sell
122,066
-42,467
-26% -$1.7M ﹤0.01% 3345
2021
Q3 		$5.48M Buy
164,533
+112,951
+219% +$3.44M ﹤0.01% 3283
2021
Q2 		$1.42M Buy
51,582
+8,998
+21% +$187K ﹤0.01% 4495
2021
Q1 		$855K Buy
42,584
+30,067
+240% +$878K ﹤0.01% 4728
2020
Q4 		$413K Sell
12,517
-77,213
-86% -$2.05M ﹤0.01% 4721
2020
Q3 		$1.61M Buy
+89,730
New +$1.63M ﹤0.01% 3720

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Goldman Sachs's INBX Position: Q2 2024 in Review

Goldman Sachs sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 376,540 shares — an estimated $13.2M sold.

Goldman Sachs first reported a position in INBX in Q3 2020 and held it in 15 quarters. The position peaked at $13.2M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Goldman Sachs reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 376,540 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $13.2M.
  • Goldman Sachs first reported a position in Inhibrx, Inc. Common Stock in Q3 2020 and held it in 15 quarters.
  • Goldman Sachs's Inhibrx, Inc. Common Stock position peaked at $13.2M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.